Human Genome Sciences Boosts Cancer Pipeline
By Business Review Editor
Pharma Deals Review: Vol 2008 Issue 92 (Table of Contents)
Published: 8 Feb-2008
DOI: 10.3833/pdr.v2008.i92.223 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Human Genome Sciences (HGS) received a major boost to its cancer pipeline by initiating a Phase II trial of its human monoclonal antibody HGS-ETRI (mapatumumab) and also licensed rights to Aegera Therapeutics’ AEG40826 anticancer compound and backup compounds...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS